Multiple nano-drug delivery systems for intervertebral disc degeneration: Current status and future perspectives

Liu, Wenzhao; Ma, Zhanjun; Wang, Yonggang; Yang, Jingjing

doi:10.1016/j.bioactmat.2022.11.006

Cited by 43 publications

(31 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Well-designed nanocarriers can target special tissue and/or cells through specific interaction with biomacromolecules and receptors (Liu et al, 2022;Bhaladhare and Bhattacharjee, 2023). Since the approval of adriamycin liposomes in 1995, nearly 250 kinds of nanotherapeutic drugs have been studied in preclinical or clinical research, especially in cancer therapy (Zhang et al, 2015;Xu et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review

Yang

Miao²,

Yu³

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Macrophages are involved in the whole process of atherosclerosis, which is characterized by accumulation of lipid and inflammation. Presently, clinically used lipid-lowering drugs cannot completely retard the progress of atherosclerosis. Liver X receptor (LXR) plays a key role in regulation of lipid metabolism and inflammation. Accumulating evidence have demonstrated that synthetic LXR agonists can significantly retard the development of atherosclerosis. However, these agonists induce sever hypertriglyceridemia and liver steatosis. These side effects have greatly limited their potential application for therapy of atherosclerosis. The rapid development of drug delivery system makes it possible to delivery interested drugs to special organs or cells using nanocarriers. Macrophages express various receptors which can recognize and ingest specially modified nanocarriers loaded with LXR agonists. In the past decades, a great progress has been made in this field. These macrophage-targeted nanocarriers loaded with LXR agonists are found to decrease atherosclerosis by reducing cholesterol accumulation and inflammatory reactions. Of important, these nanocarriers can alleviate side effects of LXR agonists. In this article, we briefly review the roles of macrophages in atherosclerosis, mechanisms of action of LXR agonists, and focus on the advances of macrophage-targeted nanocarriers loaded with LXR agonists. This work may promote the potential clinical application of these nanocarriers.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review

Yang

Miao²,

Yu³

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…This results in the production of nerve growth factor (NGF), leading to abnormal inward nerve growth in the disc tissue . The interaction between the inflammatory mediators in the disc and the new nerve fibers causes discogenic pain . In addition, with the calcification of CEP and sclerosis of the bone marrow space, the nutrients in the IVD gradually decreased, and there is an imbalance between supply and demand of nutrients, further leading to the degradation of ECM. , As this change persists, AF and NP will also be affected, eventually leading to disc dysfunction and degeneration.…”

Section: Intervertebral Disc Physiologymentioning

confidence: 99%

Reviving Intervertebral Discs: Treating Degeneration Using Advanced Delivery Systems

Zhang,

Yang,

Huang

et al. 2024

Mol. Pharmaceutics

View full text Add to dashboard Cite

Intervertebral disc degeneration (IVDD) is commonly associated with many spinal problems, such as low back pain, and significantly impacts a patient's quality of life. However, current treatments for IVDD, which include conservative and surgical methods, are limited in their ability to fully address degeneration. To combat IVDD, delivery-system-based therapy has received extensive attention from researchers. These delivery systems can effectively deliver therapeutic agents for IVDD, overcoming the limitations of these agents, reducing leakage and increasing local concentration to inhibit IVDD or promote intervertebral disc (IVD) regeneration. This review first briefly introduces the structure and function of the IVD, and the related pathophysiology of IVDD. Subsequently, the roles of drug-based and bioactive-substance-based delivery systems in IVDD are highlighted. The former includes natural source drugs, nonsteroidal anti-inflammatory drugs, steroid medications, and other small molecular drugs. The latter includes chemokines, growth factors, interleukin, and platelet-rich plasma. Additionally, gene-based and cell-based delivery systems are briefly involved. Finally, the limitations and future development of the combination of therapeutic agents and delivery systems in the treatment of IVDD are discussed, providing insights for future research.

show abstract

“…14,15 Their primary objective is to achieve precise distribution to specific cells or tissues while simultaneously minimizing adverse effects in nontargeted areas of the body. 16 Extensive research has been conducted on several drug delivery platforms, including nanoparticles such as polymeric micelles, niosomes, metal nanoparticles, nanospheres, dendrimers, and liposomes, due to their potential applicability in various disease fields. 17−22 Micelles typically have dimensions within the range of 10−100 nm, and they form through the self-assembly process of amphiphilic block copolymers, such as poly-(ethylene glycol)-block-poly(D,L-lactide) (PEG-b-PLA) and poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL).…”

Section: ■ Introductionmentioning

confidence: 99%

“…Drug delivery systems are advanced technologies developed to facilitate the transportation of therapeutic agents into the human body. These systems have the potential to significantly improve medication solubility, stability, safety, and efficacy in the diagnosis and treatment of a wide range of disorders. , Their primary objective is to achieve precise distribution to specific cells or tissues while simultaneously minimizing adverse effects in nontargeted areas of the body . Extensive research has been conducted on several drug delivery platforms, including nanoparticles such as polymeric micelles, niosomes, metal nanoparticles, nanospheres, dendrimers, and liposomes, due to their potential applicability in various disease fields. − Micelles typically have dimensions within the range of 10–100 nm, and they form through the self-assembly process of amphiphilic block copolymers, such as poly(ethylene glycol)- block -poly( d , l -lactide) (PEG- b -PLA) and poly(ethylene glycol)- block -poly(ε-caprolactone) (PEG- b -PCL) .…”

Section: Introductionmentioning

confidence: 99%

In Vitro Tracking of Sporozoites via Fluorescence Imaging and MRI Using Multifunctional Micelles

Assawapanumat,

Roobsoong,

Chotivanich

et al. 2023

ACS Appl. Bio Mater.

View full text Add to dashboard Cite

Multiple nano-drug delivery systems for intervertebral disc degeneration: Current status and future perspectives

Cited by 43 publications

References 196 publications

Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review

Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review

Reviving Intervertebral Discs: Treating Degeneration Using Advanced Delivery Systems

In Vitro Tracking of Sporozoites via Fluorescence Imaging and MRI Using Multifunctional Micelles

Contact Info

Product

Resources

About